Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.

Abstract

We analyzed 186 patients with lymphoma who underwent allogeneic stem cell transplantation (ASCT) with fludarabine-melphalan (FM) conditioning and different types of donors (25 haploidentical [HD], 98 matched unrelated [MUD], and 63 matched related [MRD]) at our institution between September 2009 and January 2018. Patients received fludarabine 160 mg/m2 (40 mg/m2/day for 4 days) in combination with 1 dose of melphalan 140 mg/m2 (FM140) or 100 mg/m2 (FM100). Engraftment was similar among the 3 groups (92%, 89%, and 98%, respectively; P = .7). The 6-month cumulative incidence of grade III-IV acute graft-versus-host disease (GVHD) was 4% in the HD group, 14% in the MUD group, and 8% in the MRD group (P not significant), and the respective 3-year cumulative incidence of chronic GVHD was 5%, 16%, and 26% (P not significant). The respective 3-year nonrelapse mortality and relapse rates were 31%, 32%, and 10% (HD versus MUD, P = .9; HD versus MRD, P = .02) and 15%, 21%, and 39% (HD versus MUD, P = .4; HD versus MRD, P = .04). At 3 years, progression-free survival (PFS) was 59%, 44%, and 46% (P not significant); overall survival (OS) was 52%, 54%, and 67% (P not significant); and GVHD-free, relapse-free survival was 39%, 31%, and 24% (P not significant). No differences in the 3-year PFS (57% versus 43%; P = .3) and OS (64% versus 58%; P = .7) were seen between patients receiving FM100 and those receiving FM140. Our data demonstrate that in patients with lymphoma, ASCT with HD transplants have similar outcomes as ASCT with HLA-matched transplants, and the FM100 conditioning regimen appears to be at least as effective as the FM140 regimen.

• Authors: Neeraj Y Saini, Rima M Saliba, Gabriela Rondon, Farzaneh Maadani, Uday Popat, Chitra M Hosing, Betul Oran, Qaiser Bashir, Amanda Olson, Yago Nieto, Amin Alousi, Partow Kebriaei, Samer Srour, Rohtesh Mehta, Paolo Anderlini, Elizabeth J Shpall, Muzaffar H Qazilbash, Issa F Khouri, Luis Fayad, Hun Lee, Nathan Fowler, Simrit Parmar, Jason Westin, Fredrick Hagemeister, Richard E Champlin, Stefan O Ciurea
• Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (Biol Blood Marrow Transplant) Vol. 25 Issue 7 Pg. 1340-1346 (07 2019) ISSN: 1523-6536 [Electronic] United States
• PMID: 30763728 (Publication Type: Clinical Trial, Journal Article)
• Copyright: Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Chemical References

• Vidarabine
• fludarabine
• Melphalan

Topics

• Adolescent
• Adult
• Aged
• Allografts
• Disease-Free Survival
• Female
• Graft vs Host Disease (etiology, mortality, therapy)
• Humans
• Incidence
• Lymphoma (mortality, therapy)
• Male
• Melphalan (administration & dosage)
• Middle Aged
• Retrospective Studies
• Stem Cell Transplantation
• Survival Rate
• Tissue Donors
• Vidarabine (administration & dosage, analogs & derivatives)